Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 10th January 2022
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

PetMedix and Zoetis to collaborate on antibody therapies
"Collaborating with PetMedix complements our own research and development activities, and we are pleased to be working with them to explore areas of unmet clinical needs in pets" - Robert J. Polzer, Zoetis.

Firms will use transgenic platforms for antibody discovery.

PetMedix has joined forces with Zoetis to develop new species-specific
animal monoclonal antibody therapies (mAbs) using its proprietary transgenic platforms.

Through the partnership, PetMedix will carry out discovery activities against a number of key targets, while Zoetis will have exclusive rights to develop and bring these therapies to market.

Having already brought three novel mAbs to market, Zoetis is a leader in companion animal antibody therapeutics, including fully species-specific antibodies.

PetMedix chief executive Dr Tom Weaver commented: "We are excited to be partnering with Zoetis. Bringing together our unique pet antibody discovery engine with their proven ability to not just develop antibodies, but also make them a commercial success, is set to be a winning combination."

While many technologies have been used to develop human therapeutic antibodies, 40 years of research highlights the benefits of antibodies which are 100 per cent species-matched to the patient.

PetMedix is looking to build on this success for companion animals. Its Ky9™ and Felyne™ platforms were developed in the same way as the leading human transgenic platforms. The collaboration also marks the third publicly-announced deal Zoetis has made with companies using transgenic platforms for antibody discovery.

Zoetis executive vice president and president Robert J. Polzer, said: "At Zoetis, we are committed to continuing our leadership to develop and discover new therapeutic antibodies that can help pets live longer, healthier lives. Collaborating with PetMedix complements our own research and development activities, and we are pleased to be working with them to explore areas of unmet clinical needs in pets."

Image (C) PetMedix.

Become a member or log in to add this story to your CPD history

VMD invites students to apply for EMS placement

News Story 1
 The Veterinary Medicines Directorate (VMD) is inviting applications from veterinary students to attend a one-week extramural studies (EMS) placement in July 2026.

Students in their clinical years of study have until 28 February to apply for the placement, which takes place at the VMD's offices in Addlestone, Surrey, from 6-10 July 2026.

Through a mixture of lectures and workshops, the placement will explore how veterinary medicines are authorised, non-clinical career opportunities, and other important aspects of the VMD's work.  

Click here for more...
News Shorts
RCVS members invited to question Council candidates

RCVS members have been invited to submit questions to candidates for this year's RCVS Council election.

With 15 candidates standing for three available positions, vets have been invited to submit a question of their choosing before voting starts. These questions will be collated, with each candidate answering one question of their choice.

It is recommended that members read the candidates' biographies and statements before submitting questions. One question per member can be submitted to vetvote26@rcvs.org.uk before Wednesday, 25 February 2026.

The RCVS Council election is due to start in March.

With only two candidates for two positions on the VN Council, there will be no VN Council elections this year. Meghan Conroy RVN and Lauren Hargrave RVN will begin their three year terms at RCVS' AGM in July.